The overall ratings of five Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Momenta Pharmaceuticals‘s (NASDAQ:MNTA) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Momenta Pharmaceuticals is a biotechnology company. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Margin Growth, and Sales Growth, MNTA also gets F’s. The stock price has dropped 23.8% over the past month, worse than the 5.3% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at MNTA, get Portfolio Grader’s complete analysis of MNTA stock.
Vical Inc. (NASDAQ:VICL) gets weaker ratings this week as last week’s C drops to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Wall Street appears to agree with the stock downgrade, with share prices dropping 22.4% over the past month. For more information, get Portfolio Grader’s complete analysis of VICL stock.
Progenics Pharmaceuticals (NASDAQ:PGNX) experiences a ratings drop this week, going from last week’s C to a D. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. In Earnings Momentum, Earnings Revisions, Equity, and Sales Growth the stock gets F’s. The stock price has fallen 41.1% over the past month. For a full analysis of PGNX stock, visit Portfolio Grader.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) earns a D this week, moving down from last week’s grade of C. OncoGenex Pharmaceuticals is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients. The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. Wall Street appears to agree with the stock downgrade, with share prices dropping 12.9% over the past month. For more information, get Portfolio Grader’s complete analysis of OGXI stock.
The rating of YM BioSciences (AMEX:YMI) slips from a C to a D. YM BioSciences is a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. The stock also gets an F in Equity. To get an in-depth look at YMI, get Portfolio Grader’s complete analysis of YMI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.